Our team has developed a novel anticancer immunotherapy in which they genetically engineer the most abundant immune cell type in our blood – Neutrophil.
In this invention, a novel anticancer immunotherapeutic S3KO-TAN can be mass produced by editing human neutrophils with the latest genome engineering technology CRISPR/Cas9. S3KO-TAN shows pronounced anticancer N1 phenotype and effectively inhibits the growth of human lung cancer in animal models. Neutrophils are suitable for allogenic use without antigen pairing and can be easily obtained from blood by-products, markedly overcoming the unsolved barriers of the T-cell immunotherapy. The research team wishes to translate S3KO-TAN into an effective and safe anticancer immunotherapy in the future.
Uniqueness and Competitive Advantages:
- Effectively targets solid cancer
- Allogenic use, no need antigen matching
- Safe without side-effects
- Mass produce without ex vivo cell expansion
- Unlimited source from blood donation by-product